1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 67, 2016
  5. Article

Annual Review of Medicine

Volume 67, 2016

Vaccination Against Dengue: Challenges and Current Developments

Abstract

Dengue is a growing threat worldwide, and the development of a vaccine is a public health priority. The completion of the active phase of two pivotal efficacy studies conducted in Asia and Latin America by Sanofi Pasteur has constituted an important step. Several other approaches are under development, and whichever technology is used, vaccine developers face several challenges linked to the particular nature and etiology of dengue disease. We start our review by defining questions and potential issues linked to dengue pathology and presenting the main types of vaccine approaches that have explored these questions; some of these candidates are in a late stage of clinical development. In the second part of the review, we focus on the Sanofi Pasteur dengue vaccine candidate, describing the steps from research to phase III efficacy studies. Finally, we discuss what could be the next steps, before and after vaccine introduction, to ensure that the vaccine will provide the best benefit with an acceptable safety profile to the identified target populations.

Keyword(s): clinical trials, flavivirus, human, immunology, safety, vaccine
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-091014-090848
2016-01-14
2024-06-02
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-091014-090848.html?itemId=/content/journals/10.1146/annurev-med-091014-090848&mimeType=html&fmt=ahah

Literature Cited

  1. Bhatt S, Gething PW, Brady OJ. 1.  et al. 2013. The global distribution and burden of dengue. Nature 496:504–7 [Google Scholar]
  2. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. 2.  2004. Dengue viral infections. Postgrad. Med. J. 80:588–601 [Google Scholar]
  3. 3. WHO 2009. Dengue guidelines for diagnosis, treatment, prevention and control. http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
  4. Vaughn DW, Green S, Kalayanarooj S. 4.  et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2–9 [Google Scholar]
  5. Martina BE, Koraka P, Osterhaus AD. 5.  2009. Dengue virus pathogenesis: an integrated view. Clin. Microbiol. Rev. 22:564–81 [Google Scholar]
  6. Guzman MG, Halstead SB, Artsob H. 6.  et al. 2010. Dengue: a continuing global threat. Nat. Rev. Microbiol. 12:S7–S16 [Google Scholar]
  7. Rothman AL. 7.  2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11:532–43 [Google Scholar]
  8. Kyle JL, Beatty PR, Harris E. 8.  2007. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J. Infect. Dis. 195:1808–17 [Google Scholar]
  9. Cerny D, Haniffa M, Shin A. 9.  et al. 2014. Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog. 10:e1004548 [Google Scholar]
  10. Ho LJ, Wang JJ, Shaio MF. 10.  et al. 2001. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 166:1499–506 [Google Scholar]
  11. Schmid MA, Harris E. 11.  2014. Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog. 10:e1004541 [Google Scholar]
  12. Lin YW, Wang KJ, Lei HY. 12.  et al. 2002. Virus replication and cytokine production in dengue virus-infected human B lymphocytes. J. Virol. 76:12242–49 [Google Scholar]
  13. Wang JP, Liu P, Latz E. 13.  et al. 2006. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J. Immunol. 177:7114–21 [Google Scholar]
  14. Palmer DR, Sun P, Celluzzi C. 14.  et al. 2005. Differential effects of dengue virus on infected and bystander dendritic cells. J. Virol. 79:2432–39 [Google Scholar]
  15. Azeredo EL, De Oliveira-Pinto LM, Zagne SM. 15.  et al. 2006. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin. Exp. Immunol. 143:345–56 [Google Scholar]
  16. Hershkovitz O, Zilka A, Bar-Ilan A. 16.  et al. 2008. Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells. J. Virol. 82:7666–76 [Google Scholar]
  17. Green AM, Beatty PR, Hadjilaou A, Harris E. 17.  2014. Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426:1148–60 [Google Scholar]
  18. King CA, Anderson R, Marshall JS. 18.  2002. Dengue virus selectively induces human mast cell chemokine production. J. Virol. 76:8408–19 [Google Scholar]
  19. Vervaeke P, Vermeire K, Liekens S. 19.  2015. Endothelial dysfunction in dengue virus pathology. Rev. Med. Virol. 25:50–67 [Google Scholar]
  20. Medin CL, Fitzgerald KA, Rothman AL. 20.  2005. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J. Virol. 79:11053–61 [Google Scholar]
  21. Souza DG, Fagundes CT, Sousa LP. 21.  et al. 2009. Essential role of platelet-activating factor receptor in the pathogenesis of dengue virus infection. PNAS 106:14138–43 [Google Scholar]
  22. Avirutnan P, Mehlhop E, Diamond MS. 22.  2008. Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 26:Suppl. 8100–7 [Google Scholar]
  23. Shresta S. 23.  2012. Role of complement in dengue virus infection: protection or pathogenesis?. mBio 3:e00003–12 [Google Scholar]
  24. Warke RV, Martin KJ, Giaya K. 24.  et al. 2008. TRAIL is a novel antiviral protein against dengue virus. J. Virol. 82:555–64 [Google Scholar]
  25. Mathew A, West K, Kalayanarooj S. 25.  et al. 2011. B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204:1514–22 [Google Scholar]
  26. Weiskopf D, Angelo MA, de Azeredo EL. 26.  et al. 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD+ T cells. PNAS 110:2046–53 [Google Scholar]
  27. Zellweger RM, Eddy WE, Tang WW. 27.  et al. 2014. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J. Immunol. 193:4117–24 [Google Scholar]
  28. Zellweger RM, Miller R, Eddy WE. 28.  et al. 2013. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 9:e1003723 [Google Scholar]
  29. Laoprasopwattana K, Libraty D, Endy TP. 29.  et al. 2007. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J. Infect. Dis. 195:1108–16 [Google Scholar]
  30. Montoya M, Gresh L, Mercado JC. 30.  et al. 2013. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Trop. Dis. 7:e2357 [Google Scholar]
  31. Olkowski S, Forshey BM, Morrison AC. 31.  et al. 2013. Reduced risk of disease during postsecondary dengue virus infections. J. Infect. Dis. 208:1026–33 [Google Scholar]
  32. Endy TP, Anderson KB, Nisalak A. 32.  et al. 2011. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl. Trop. Dis. 5:e975 [Google Scholar]
  33. Anderson KB, Gibbons RV, Cummings DA. 33.  et al. 2009. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209:360–68 [Google Scholar]
  34. Sabin AB. 34.  1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30–50 [Google Scholar]
  35. Snow GE, Haaland B, Ooi EE, Gubler DJ. 35.  2014. “Research on Dengue During World War II” revisited. Am. J. Trop. Med. Hyg. 91:1203–17 [Google Scholar]
  36. Halstead SB, Mahalingam S, Marovich MA. 36.  et al. 2010. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10:712–22 [Google Scholar]
  37. Fink J, Gu F, Ling L. 37.  et al. 2007. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1:e86 [Google Scholar]
  38. Long HT, Hibberd ML, Hien TT. 38.  et al. 2009. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J. Infect. Dis. 199:537–46 [Google Scholar]
  39. Simmons CP, Popper S, Dolocek C. 39.  et al. 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195:1097–107 [Google Scholar]
  40. Coller BA, Barrett AD, Thomas SJ. 40.  2011. The development of dengue vaccines. Introduction. Vaccine 29:7219–20 [Google Scholar]
  41. Kanesa-Thasan N, Edelman R, Tacket CO. 41.  et al. 2003. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am. J. Trop. Med. Hyg. 69:6 Suppl.17–23 [Google Scholar]
  42. Sabchareon A, Lang J, Chanthavanich P. 42.  et al. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264–72 [Google Scholar]
  43. Sanchez V, Gimenez S, Tomlinson B. 43.  et al. 2006. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24:4914–26 [Google Scholar]
  44. Guy B, Barrere B, Malinowski C. 44.  et al. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229–41 [Google Scholar]
  45. Durbin AP, Kirkpatrick BD, Pierce KK. 45.  et al. 2011. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242–50 [Google Scholar]
  46. Kirkpatrick BD, Durbin AP, Pierce KK. 46.  et al. 2015. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212:702–10 [Google Scholar]
  47. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. 47.  2011. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29:7251–60 [Google Scholar]
  48. George SL, Wong MA, Dube TJ. 48.  et al. 2015. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J. Infect. Dis. 212:1032–41 [Google Scholar]
  49. Coller BA, Clements DE, Bett AJ. 49.  et al. 2011b. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267–75 [Google Scholar]
  50. Schmitz J, Roehrig J, Barrett A, Hombach J. 50.  2011. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29:7276–84 [Google Scholar]
  51. Diaz C, Lin L, Martinez LJ. 51.  et al. 2014. Phase 1 study of different formulations of a tetravalent dengue purified inactivated vaccine (DPIV): safety and immunogenicity data in healthy adults from Puerto Rico through month 7. Am. J. Trop. Med. Hyg. 91:Abstr. LB–3137 [Google Scholar]
  52. Guy B, Guirakhoo F, Barban V. 52.  et al. 2010. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28:632–49 [Google Scholar]
  53. 53. WHO Expert Committee on Biological Standardization 2011. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). WHO Tech. Rep. Ser. No. 979, Annex 2 (replacement of Annex 1 of WHO Tech. Rep. Ser. No. 932) Geneva: World Health Organ. [Google Scholar]
  54. Monath TP, Seligman SJ, Robertson JS. 54.  et al. 2015. Brighton Collab. Viral Vector Vaccines Safety Working Group (V3SWG). Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33:162–72 [Google Scholar]
  55. Monath TP, Myers GA, Beck RA. 55.  et al. 2005. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33:131–44 [Google Scholar]
  56. Mantel N, Girerd Y, Geny C. 56.  et al. 2011. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29:6629–35 [Google Scholar]
  57. Dubayle J, Vialle S, Schneider D. 57.  et al. 2015. Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine. Vaccine 33:1360–68 [Google Scholar]
  58. Brandler S, Brown N, Ermak TH. 58.  et al. 2005. Replication of chimeric yellow fever virus-dengue serotype 1–4 virus vaccine strains in dendritic and hepatic cells. Am. J. Trop. Med. Hyg. 72:74–81 [Google Scholar]
  59. Deauvieau F, Sanchez V, Balas C. 59.  et al. 2007. Innate immune responses in human dendritic cells upon infection by chimeric yellow fever dengue vaccines serotype 1 to 4. Am. J. Trop. Med. Hyg. 76:144–54 [Google Scholar]
  60. Balas C, Kennel A, Deauvieau F. 60.  et al. 2011. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1–4 vaccine virus strains. J. Infect. Dis. 203:103–8 [Google Scholar]
  61. Guirakhoo F, Pugachev K, Zhang Z. 61.  et al. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761–75 [Google Scholar]
  62. Guy B, Barban V, Mantel M. 62.  et al. 2009. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80:302–11 [Google Scholar]
  63. Barban V, Mantel N, Harenberg A. 63.  et al. 2014. Protective immunity induced against DENV-2 intravenous challenge in non-human primates immunized with CYD vaccine clinical lots. Am. J. Trop. Med. Hyg. 91:Abstr. LB–3233 [Google Scholar]
  64. Guy B, Boaz M, Byers A. 64.  et al. 2014. Assessment of the qualitative immune response induced by the CYD tetravalent vaccine in human volunteers. Am. J. Trop. Med. Hyg. 91:Abstr. 575 [Google Scholar]
  65. Ravel G, Guy B, Mantel N. 65.  et al. 2012. Sanofi Pasteur live attenuated, tetravalent dengue vaccine toxicity, biodistribution and shedding study in cynomolgus monkeys. Am. J. Trop. Med. Hyg. 87:Abstr. 630 [Google Scholar]
  66. Higgs S, Vanlandingham DL, Klingler KA. 66.  et al. 2006. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am. J. Trop. Med. Hyg. 75:986–93 [Google Scholar]
  67. Kazimírová M, Mantel N, Raynaud S. 67.  et al. 2012. Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks. Vector Borne Zoonotic Dis 12:979–85 [Google Scholar]
  68. McGee CE, Tsetsarkin KA, Guy B. 68.  et al. 2011. Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS ONE 6:8e23247 [Google Scholar]
  69. McGee CE, Lewis MG, Claire MS. 69.  et al. 2008. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197:693–97 [Google Scholar]
  70. McGee CE, Tsetsarkin K, Vanlandingham DL. 70.  et al. 2008. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J. Infect. Dis. 197:686–92 [Google Scholar]
  71. Lefeuvre A. 71.  2005. Caractérisation des interactions entre les cellules hépatiques et les souches sauvage et vaccinale du virus de la fièvre jaune: application à l'étude de virus fièvre jaune chimériques utilisés pour le développement d'un vaccin contre la dengue Diplôme de Doctorat, Univ. Claude Bernard Lyon 1, No. 129–2005
  72. Guy B, Chanthavanich P, Gimenez S. 72.  et al. 2004. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22:3563–74 [Google Scholar]
  73. Byers A, Broder R, Moser J. 73.  et al. 2014. Serotype-specific dengue neutralizing antibody responses in FcgR expressing CV1 cells. Abstr. 833. Am. J. Trop. Med. Hyg. 91:228–303 [Google Scholar]
  74. Timiryasova TM, Bonaparte MI, Luo P. 74.  et al. 2013. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am. J. Trop. Med. Hyg. 88:962–70 [Google Scholar]
  75. Roehrig JT, Hombach J, Barrett AD. 75.  2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral. Immunol. 21:123–32 [Google Scholar]
  76. Morrison D, Legg TJ, Billings CW. 76.  et al. 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201:370–77 [Google Scholar]
  77. Poo J, Galan F, Forrat R. 77.  et al. 2011. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. 30:e9–e17 [Google Scholar]
  78. Capeding RZ, Luna IA, Bomasang E. 78.  et al. 2011. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29:3863–72 [Google Scholar]
  79. Lanata CF, Andrade T, Gil AI. 79.  et al. 2012. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 30:5935–41 [Google Scholar]
  80. Leo YS, Wilder-Smith A, Archuleta S. 80.  et al. 2012. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: phase II randomized controlled trial in Singapore. Hum. Vaccin. Immunother. 8:1259–71 [Google Scholar]
  81. Qiao M, Shaw D, Forrat R. 81.  et al. 2011. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am. J. Trop. Med. Hyg. 85:724–31 [Google Scholar]
  82. Guirakhoo F, Kitchener S, Morrison D. 82.  et al. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2:60–67 [Google Scholar]
  83. Guy B, Nougarede N, Begue S. 83.  et al. 2008. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26:5712–21 [Google Scholar]
  84. Harenberg A, Begue S, Mamessier A. 84.  et al. 2013. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum. Vaccin. Immunother. 9:2317–25 [Google Scholar]
  85. Dayan G, Galán-Herrera GF, Forrat R. 85.  et al. 2014. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum. Vaccin. Immunother. 10:2853–63 [Google Scholar]
  86. Sabchareon A, Wallace D, Sirivichayakul C. 86.  et al. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559–67 [Google Scholar]
  87. Capeding MR, Tran NH, Hadinegoro SR. 87.  et al. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358–65 [Google Scholar]
  88. Villar L, Dayan GH, Arredondo-García JL. 88.  et al. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372:113–23 [Google Scholar]
  89. Hadinegoro SRS, Arredondo-García JL, Capeding MR. 89.  et al. 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373:1195–206 [Google Scholar]
  90. Gamble J, Bethell D, Day NP. 90.  et al. 2000. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?. Clin. Sci. 98:211–16 [Google Scholar]
  91. Hanna-Wakim R, Yasukawa LL, Sung P. 91.  et al. 2009. Age-related increase in the frequency of CD4+ T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J. Infect. Dis. 200:1921–27 [Google Scholar]
  92. Jackson N, Boaz M, Hu B. 92.  et al. 2014. Investigations of the observed efficacy of the CYD tetravalent dengue vaccine in the phase 2b trial in Ratchaburi, Thailand. Abstr. 576. Am. J. Trop. Med. Hyg. 91:149–228 [Google Scholar]
  93. Thomas SJ. 93.  2013. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum. Vaccin. Immunother. 9:1587–90 [Google Scholar]
/content/journals/10.1146/annurev-med-091014-090848
Loading
Vaccination Against Dengue: Challenges and Current Developments
Annual Review of Medicine 67, 387 (2016); https://doi.org/10.1146/annurev-med-091014-090848
/content/journals/10.1146/annurev-med-091014-090848
/content/journals/10.1146/annurev-med-091014-090848
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error